Overall, our work reveals new signaling pathways that control PNPLA3 transcription, and highlights momelotinib as a drug candidate for treating a substantial genetically defined subpopulation of NAFLD/NASH patients. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.